<SEC-DOCUMENT>0001144204-18-014662.txt : 20180314
<SEC-HEADER>0001144204-18-014662.hdr.sgml : 20180314
<ACCEPTANCE-DATETIME>20180314163044
ACCESSION NUMBER:		0001144204-18-014662
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180314
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180314
DATE AS OF CHANGE:		20180314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AmpliPhi Biosciences Corp
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		18689836

	BUSINESS ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		804-827-2524

	MAIL ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv488534_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report (Date of earliest event
reported): March 14, 2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-37544 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AmpliPhi
Biosciences Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of Registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Washington</B></FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>91-1549568</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(State or other
jurisdiction of incorporation or organization)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(IRS Employer Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3579 Valley Centre Drive, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California 92130</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(858) 829-0829</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s Telephone number)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect; 240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item 2.02 </B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2018, we announced our financial
results for the quarter and year ended December 31, 2017 in the press release attached hereto as Exhibit 99.1 and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 2.02 and the
attached Exhibit 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02
and the attached exhibit shall not be incorporated by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item 9.01 </B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial Statements and Exhibits. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(d) </B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibits. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding: 0; text-indent: 0; width: 0.75in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit<BR>
        No.</B></P></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 0.25in">&nbsp;</TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
<TR>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center; padding: 0; text-indent: 0"><A HREF="tv488534_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><A HREF="tv488534_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">Press release issued by AmpliPhi Biosciences Corporation on March 14, 2018 relating to financial results</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: March 14, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AmpliPhi Biosciences Corporation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv488534_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; text-align: right">
    <TD STYLE="width: 50%; text-align: left">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 44.15pt; width: 165.35pt"></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; color: #7030A0">AmpliPhi
Biosciences Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7030A0">3579 Valley Centre Drive,
Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7030A0">&#9;San Diego, CA 92130</P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: rgb(111,47,160) 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AmpliPhi
Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Announced positive topline results for the first seven patients
treated with AB-SA01 or AB-PA01 under ongoing expanded access program. Treatment was well tolerated with 86% of patients achieving
treatment success</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signed a Cooperative Research and Development Agreement with the
U.S. Department of Veterans Affairs</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Completed a public offering of common stock in Jan. 2018 for gross
proceeds of $4.0 million</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>San Diego (</B></FONT><B>Mar.
14, 2018) &ndash; AmpliPhi Biosciences Corporation (NYSE American: APHB)</B>, a clinical-stage biotechnology company focused on
precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the fourth
quarter and full year ended December 31, 2017. AmpliPhi Biosciences will not be conducting a conference call in conjunction with
this financial release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I&rsquo;m delighted to report that AmpliPhi made progress
in the fourth quarter and into 2018,&rdquo; said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. &ldquo;The highlight of the
period was the announcement of positive topline results from our expanded access program to treat severely ill patients with AB-SA01
or AB-PA01, our bacteriophage therapeutic candidates targeting resistant <I>Staphylococcus aureus</I> and <I>Pseudomonas aeruginosa</I>
infections. Expansion of this innovative and potentially life-saving program continues, as evidenced by the collaboration agreement
we recently signed with the U.S. Department of Veteran Affairs. Our plan remains to bring the data to the FDA in mid-2018, obtain
feedback on the path to regulatory approval, and potentially initiate a Phase 2 or registrational clinical study as early as the
second half of 2018.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Announced
positive topline results for the first seven patients treated under ongoing single-patient expanded access program. Six of the
seven patients (86%) achieved treatment success (physician&rsquo;s assessment), defined as complete resolution or significant
improvement of baseline signs and symptoms. All patients were severely ill with life-threatening infections and unresponsive to
antibiotics at the time of treatment.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provided
a corporate update during an investor conference call on January 3, 2018, outlining the company&rsquo;s 2018 clinical strategy
and the various approaches the company is taking to fund Phase 2 clinical development of its bacteriophage therapeutics.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed
a public offering of 4,000,000 shares of common stock in January 2018, at a price to the public of $1.00 per share, for gross
proceeds of $4.0 million.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signed
a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs covering expanded access
treatment for AB-SA01 and AB-PA01. Mark Holodniy, M.D., Professor of Medicine (infectious diseases) at Stanford University and
the Veterans Affairs Palo Alto Health Care System and Director of the Public Health Surveillance for the Department of Veterans
Affairs, will be the Principal Investigator leading the collaboration.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fourth Quarter 2017 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development (R&amp;D) expenses for the fourth quarter
of 2017 were $1.1 million compared to $0.8 million for the fourth quarter of 2016.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative (G&amp;A) expenses were $1.3 million for
the fourth quarter of 2017 compared to $1.5 million for the fourth quarter of 2016. The decrease was primarily due to a decrease
in non-cash stock-based compensation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Full-Year 2017 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">R&amp;D
expenses for 2017 were $2.9 million compared to $5.7 million for 2016. The decrease was due to lower professional and consulting
fees and clinical expenses. R&amp;D expenses were offset by $2.0 million in tax rebates from the Australian government for qualified
R&amp;D expenditures in 2017 compared to $0.9 million in 2016.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">G&amp;A
expenses for 2017 were $7.6 million compared to $8.4 million in 2016. The decrease was primarily attributable to decreases in
non-cash stock-based compensation and other charges in 2017.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities for 2017 was $9.2 million compared to $10.6 million for 2016.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents as of December 31, 2017 totaled $5.1 million.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 14, 2018, there were 13.7 million shares of common stock outstanding.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
audit opinion included in the company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2017 contains a going
concern explanatory paragraph. The company is exploring multiple financing options.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About AmpliPhi Biosciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AmpliPhi Biosciences Corporation is a clinical-stage
biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for patients with serious and
life-threatening antibiotic-resistant bacterial infections. AmpliPhi&rsquo;s lead product candidates, AB-SA01 and AB-PA01, target
multidrug-resistant&nbsp;<I>Staphylococcus aureus </I>and <I>Pseudomonas aeruginosa,&nbsp;</I>which are included on the WHO&rsquo;s
2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic resistance as they
can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms
(a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to
restore antibiotic sensitivity to drug-resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Statements in this press release that are
not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include, without limitation, statements regarding: AmpliPhi&rsquo;s plan to present
data from expanded access clinical cases to the FDA in mid-2018, obtain feedback on the path to regulatory approval, and potentially
initiate a Phase 2 or registrational clinical study as early as the second half of 2018; and the potential benefits of phage therapy
and the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics
or are associated with biofilms. Words such as &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;goal,&rdquo; &ldquo;potential&rdquo; and similar expressions
are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying
words. Among the factors that could cause actual results to differ materially from those indicated in these forward-looking statements
are risks and uncertainties associated with bacteriophage product candidate development, both generally and specifically through
expanded access regulations, AmpliPhi&rsquo;s financial condition, and other risks and uncertainties described in AmpliPhi&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission (SEC), and
AmpliPhi&rsquo;s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary
statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances
after the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>At the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matthew Dansey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AmpliPhi Biosciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(858) 800-4869</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">md@ampliphibio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert H. Uhl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westwicke Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(858) 356-5932</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">robert.uhl@westwicke.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Schull or Maggie Beller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(212) 845-4271</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David.Schull@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maggie.Beller@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;Condensed Consolidated Balance Sheets</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">5,132,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">5,711,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Prepaids and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">253,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">602,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,385,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,313,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">816,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,072,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,937,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,768,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,138,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">18,153,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,968,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,538,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Derivative liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">292,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,443,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred tax liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,147,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,449,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,407,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,430,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,731,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,723,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,138,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">18,153,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Condensed Consolidated Statements of Operations</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt; font-weight: bold">Revenue</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">20,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">22,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">115,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">260,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,090,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">802,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,881,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,678,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,295,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,537,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,590,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,413,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Impairment charges</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,547,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,800,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,547,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,385,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,886,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,271,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,638,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,365,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11,864,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(16,156,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23,378,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of derivative liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,791,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,010,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,538,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other income (expense), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(554,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,808,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,016,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,984,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss before income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,352,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10,056,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(14,140,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(19,394,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">556,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,302,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">556,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,352,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,500,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(12,838,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(18,838,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Excess of fair value of consideration transferred on conversion of Series B preferred stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,580,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accretion of Series B preferred stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,858,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,352,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(9,500,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(12,838,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(24,276,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock - basic</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7.02</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2.01</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(24.67</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average number of shares of common stock outstanding - basic</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,493,140</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,353,767</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,387,425</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">983,846</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock - diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7.57</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2.18</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(24.67</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average number of shares of common stock outstanding - diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,493,140</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,405,608</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,574,117</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">983,846</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Condensed Consolidated Statement of Cash Flows</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(12,838,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(18,838,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Change in fair value of derivative liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,010,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,538,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Impairment charges</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,800,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,547,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">700,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,995,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Deferred taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,302,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(556,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Charge for common stock issuance</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">519,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Costs related to equity offerings</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">569,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Warrants and other non-cash adjustments, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">193,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">374,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">369,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Changes in operating assets and liabilities, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(457,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">653,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,192,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,606,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Investing activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Purchases of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(58,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(279,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(58,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(279,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Financing activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from sale of common stock and related warrants, net of offering costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,353,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,566,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other financing activities, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(682,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(340,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,671,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,226,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net decrease in cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(579,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,659,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,711,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,370,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,132,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,711,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: right; color: #7030A0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #) O # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPU%RV/0:*Q_#/B;3O%FD#4],:0P;VC*R+M96'8C)[$'\:V*35M&#5M&%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBFR.L<;.WW5!)^@H =17+?\+"\/
M?\_,O_?EJ/\ A87A[_GYE_[\M5^SGV,_;4^Z.IHKE_\ A8/A[_GYE_[\M4\'
MCCP[.0HU%4)_YZ1LOZD8H]G/L'M8=T=#14-M=VU['YEK<13I_>C<,/TJ:H-
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M9,7<.82<+/'RC?CV^AK(K=--71Y[BXNS"BBB@D**** "NB\"_P#(Y:?]9/\
MT6U<[71>!?\ D<M/^LG_ *+:IG\+-*7QKU/::***\T]@**** "BBB@ HHHH
MP?&?B!?#'A+4-5) EBC*P@]Y&X7]2#] :^07=I'9W8LS')8G))KV7X]^(O-O
M+#P["_RPC[3< '^(Y"#\!D_\"%>,5UT8VC?N=M"-HW[GK?P(\1?8O$%UH4SX
MBOD\R$$])4'('U7/_?(KZ#KXMTK49]'U:TU&V.)[6594]R#G!]J^Q]+U&#5]
M*M-1M6S!<Q+*GT(S@^]9UXV=S+$1M+F+=%%%8'.%%%% !12,RJ,L0 .Y-,\^
M'_GK'_WT* )**165QE6##U!S2T %%%% !112,RH,LP4>I.* %HJ/SX?^>L?_
M 'T*>K*PRI!![@T +1110 44A8*"6( '<TSSX?\ GK'_ -]"@"2BH_/A_P">
ML?\ WT*>K*PRK CV- "T444 %%%% !114?GP_P#/6/\ [Z% $E%,66-SA9$)
M] U/H **** "BBB@ HIK2(F-[JN>F3BF^?#_ ,]8_P#OH4 244@8,,J00>XI
M: "H+S_CQN/^N;?RJ>H+S_CQN/\ KFW\J:W$]CY[HHK5\-017/B2P@GC62)Y
M0&1AD$5Z;=E<\5*[L95%>Z-X6T)A@Z3:_A&!6)JOPZTJ[B9K#=9S]L,60GW!
MY_(U@L1%[G5+"32TU/+;6\N;&<3VL\D,HZ,C$&O2_"7CK^TI4T_5"J73<1S
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M_D<M/^LG_HMJYVNB\"_\CEI_UD_]%M4S^%ETOC7J>TT445YI[ 4444 %%%%
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M6FSZQJUIIULN9KF58D]B3C/T'6NJ&D5<[(*T5<^P= E:?PYI<S_?DM(F;ZE
M:T:BMH$M;6*WC&(XD"*/8# J6N!GG,*^(Y/]:_\ O&OMROB.3_6O_O&NC#]3
MJPW4[SX,_P#)3+#_ *Y3?^BVKZ@KY?\ @S_R4RP_ZY3?^BVKZ@J:_P 1&(^,
M****Q, HHHH \0_:&Z^'/^WG_P!I5XA7M_[0W7PY_P!O/_M*O$*[:7P([Z/P
M(^K?A7_R3/1/^N3_ /HQJ[&N.^%?_),]$_ZY/_Z,:NQKDG\3.*?Q,*@O/^/&
MX_ZYM_*IZ@O/^/&X_P"N;?RI+<A['SW6SX2_Y&O3?^NPK&I\4TL$JRPR/'(I
MRKHQ!!]B*])JZL>-%V:9]$55O]2LM+MS/>W,<*#^\>3]!U/X5X<==UAA@ZK?
M$>AN'_QJE)+),Y>61G<]68Y-<RPW=G:\9IHC<\6>(V\1:F)$5DM805A0]?=C
M[GC\A6!0 2< 9)KT#P=X(E>:/4M6B*1H0T5NXY8]BP[#V[_SW;C3B<L8SJS.
MH\$Z0VD>'8A*NV>X/G2 ]1GH/R _$FNCHHKSY/F=V>K&*C%105X[\0O^1NG_
M .N:?^@U[%7COQ"_Y&Z?_KFG_H-;8?XSGQ?\/YG+5]$Q?ZI/]T5\[5U0^(>O
MJH E@P!C_5"MZU-SM8YL/5C3OS'L-%>/_P#"Q/$'_/6#_OT*/^%B>(/^>L'_
M 'Z%8?5YG3];IGI?B;_D6-3_ .O9_P"1KPFNEO/'6MWUG-:S20F*9"C@1 '!
MKFJZ*,'!-,Y<15C4:<3O/A?_ ,A6^_ZX#_T*O3Z\P^%__(5OO^N _P#0J]/K
MFK_&=F%_AH****Q.@\$UW_D8=3_Z^Y?_ $,U/X6_Y&G3/^OA?YU!KO\ R,.I
M_P#7W+_Z&:G\+?\ (TZ9_P!?"_SKTG\'R/'7\3Y_J=-XYU+Q+'*\$\1M=.8X
M5H"2L@_VFZ_AQ]*X*OHF2..:-HY45T8896&01[BN%U[X<V]SNN-(<6\O4P.?
MD/T/4?R^E<]*M%*S5CJKX>;?,G<\PHJU?Z=>:9<FWO;=X91V8=?<'H1]*JUU
M;G$U;1A1110(**** "BBB@#U#X7_ /(*OO\ KN/_ $&OF.\_X_KC_KHW\Z^G
M/A?_ ,@J^_Z[C_T&OF.\_P"/ZX_ZZ-_.L(_Q)'T&7_PR"BBBM#T HHHH ***
M* "BBO1/!WPAUSQ)Y=U? Z9IS<^9*O[R0?[*?U.!Z9I.2BKLF4E%79R7AO5-
M<TO6(G\/S7*7SD*L< +&3V*\[A[$5]6>%;G7KO0X9?$=C;VE^>J0ONR/4C^$
M^P)_#I7/VEMX0^&EF8+*!6O67#$8>>3_ 'F_A'MP/051T7QAJ6O>,K&)V$%H
M2^((SP?D;[Q[_P O:L)IU%=+0\ZOBJ;DHK<])HHHKF$%%%% !115>_O8--TZ
MYOKEMD%O$TLC>BJ,G^5 'A/QY\1?:=8L_#\+YCM%\^< _P#+1A\H/T7G_@=>
M/U?UK59]<UN]U2Y/[VZF:4C/W<G@#V P/PIV@Z-<^(==L])M,":ZD"!CT4=2
MQ]@ 3^%=T5RQL>C"/)&P:7K^KZ()1I>I75F)<>9Y$I3=C.,XZXR?SK0_X3SQ
M;_T,>J?^!+?XUW__  S]J_\ T&[+_OV]'_#/VK_]!NR_[]O4\],CVE-G 'QW
MXL8$'Q'J9!X(-RW^-<]7L'_#/VK_ /0;LO\ OV]<YXS^%6I^#=&34YKR"[@,
MHB?RE8%,@X)SVXQ^(IJ<+V0XU(7LCBK"]GTW4+:^MGV3V\JRQMZ,IR/Y5]CZ
M+JL&N:)9:I;']U=0K*!G[N1R#[@Y'X5\85[[\!O$7VG2+WP_,^9+1O/@!/\
MRS8_,!]&Y_X'45XW5R,1&\;]CV&BBBN4XSA_C!_R2[6/K!_Z.2OEFOJ;XP?\
MDNUCZP?^CDKY9KKH?"=F'^$]Y_9]_P"05K?_ %WB_P#06K3^,7@/^WM*.NZ=
M%G4K)/WJ*.9HAR?JR]1[9'I69^S[_P @K6_^N\7_ *"U>RUC.3C4;1C.3C4;
M1\0T5Z9\7O ?_"-ZO_:^GQ8TN]<Y51Q!*>2OL#R1^(["N=^'_@^7QEXFBLR&
M6RBQ+=R#^% >@/J>@_$]JZE-./,=:FG'F/2?@CX(\N,^*K^+YW!2Q1AT'1I/
MQY ]L^HJ;]H/_D%Z'_UVE_\ 05KV&W@BM;>*W@C6.&) B(HP%4#  KQ[]H/_
M )!>A_\ 7:7_ -!6N:,G*I<Y82<JJ;/!J^IOA!_R2W1O^V__ *.DKY9KZF^$
M'_)+=&_[;_\ HZ2M:_PFN(^$[BBBBN0XSD?BA_R377/^N(_]#6OD^OK#XH?\
MDUUS_KB/_0UKY/KJH?"SLP_PLL6M_>6._P"R7<]OOQN\F0INQTS@\TRXNKB[
MD\RYGEF?^](Y8_F:[/X=?#]/'DFHJ^I-9?8Q&>(?,W[MW^T,8V_K7H]I^S_I
M$;@WFM7LR]Q%&L>?SW5<JD8NS+E5A%V9X%'&\LBQQHSNQ 55&23Z 5]!?"7X
M:S:"1K^M1;-0="MO;MU@4]6;T8CC'8$]SQVWAWP'X;\+D2:9IL:W &/M$I\R
M3\&/3\,5TE8U*W,K(PJ5N9604445@<X5\1R?ZU_]XU]N5\1R?ZU_]XUT8?J=
M6&ZG>?!G_DIEA_URF_\ 1;5]05\O_!G_ )*98?\ 7*;_ -%M7U!4U_B(Q'QA
M1116)@%%%% 'B'[0W7PY_P!O/_M*O$*]O_:&Z^'/^WG_ -I5XA7;2^!'?1^!
M'U;\*_\ DF>B?]<G_P#1C5V-<=\*_P#DF>B?]<G_ /1C5V-<D_B9Q3^)A4%Y
M_P >-Q_US;^53U!>?\>-Q_US;^5);D/8^>ZMZ98/J>IV]E&ZH\S[ S=!52MG
MPE_R->F_]=A7I2=DV>-%7DDSI!\+KW/.HVX'LC&KEM\+8@0;K5'<=UBB"_J2
M?Y5Z%17"Z\^YZ:PU)=#%TGPIH^C,)+:U#3#I-*=[#Z9Z?ABMJBBLVV]6;1BH
MJR04444AA7COQ"_Y&Z?_ *YI_P"@U[%7COQ"_P"1NG_ZYI_Z#6^'^,Y<7_#^
M9RU;@\'>(" 1IDN#[K_C6'7T3%_JD_W16]:HX6L<U"BJE[GB?_"&^(?^@7+^
M:_XT?\(;XA_Z!<OYK_C7MU%8_69=CH^IP[L\,N/"NN6MO)<3Z=*D4:EG8D<
M=^M8]>[>)O\ D6-3_P"O9_Y&O":WI5'--LY:])4VDCO/A?\ \A6^_P"N _\
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M25[RU9XU;%SJ/305F9W+NQ9F.22<DFNA\"_\CEI_UD_]%M7.UT7@7_D<M/\
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M_K@/_0J]/KS#X7_\A6^_ZX#_ -"KT^L:_P 9T87^&@HHHK$Z#P37?^1AU/\
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M;+^45"IMMI]!QI-MI]#Z/HHHK,R"BBB@ HHHH **** "BBB@ HHHH 0@$$$
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M>&5_,=2L#Y;&,Y;/85=-^Y9,ND_<:3U/:O!&C:IH'AB'3]9O5O+U'=FF65I
M03D#+ 'I69\0?AW9^.+6*03?9=2MU*PS[<AEZ[6'IGOVS^%.^'DWC&:PO3XP
M1EN!*/(W)&ORXY^YQU]:Q/']M\1HO$<6I^%Y=]A%"$%O$ZDD]6+H_!/88R<#
MM6:OS[F:OS[ZGE,@\:?"768U,K0QR$LH5O,M[D#KQ_\ J89[5]'>&=;C\2>&
M[#5XX_+%U$&*9SM8'##/?!!KP_4?#?Q,^(=[:Q:U:_9K> G:\RK$D><9.!\S
M'@>OX5[IX?T:#P]H%EI-NQ>.UB"!R,%CU)_$DG\:JJTTNY59II7W-*BBBL3
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M^@TS3KF_N6VP6T32R'T51D_RKQ3X?^%_&?@?QM(K:7+/I,[F"XE1TVLF?EE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D=%D0HZAE88*D9!%+10
M!Q&O_#NTO-T^E,MK.>?*/^K;Z?W?Y>U<QX7TN]TGQW86]];O#)F3&X<-^[;D
M'H:]>JA?_P#']IO_ %W;_P!%O6T:LK<K.>="/,I+0OT445B= 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
